Wolverine Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Wolverine Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-7,500	Closed	-$271K	–	1866
2019 Q4	$271K	Hold	7,500	–	–	﹤0.01%	910
2019 Q3	$204K	Hold	7,500	–	–	﹤0.01%	991
2019 Q2	$180K	Hold	7,500	–	–	﹤0.01%	1054
2019 Q1	$198K	Buy	+7,500	New	+$178K	﹤0.01%	1029
2017 Q3	–	Sell	-10,000	Closed	-$118K	–	1567
2017 Q2	$118K	Hold	10,000	–	–	﹤0.01%	1020
2017 Q1	$147K	Buy	10,000 +7,000	+233%	+$113K	﹤0.01%	891
2016 Q4	$48K	Buy	+3,000	New	+$54.4K	﹤0.01%	1010
2014 Q3	–	Sell	-150	Closed	-$8K	–	2775
2014 Q2	$8K	Buy	+150	New	+$2.14K	﹤0.01%	1931

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Wolverine Asset Management's HZNP Position: Q4 2023 in Review

Wolverine Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 39,899 shares — an estimated $4.62M sold.

Wolverine Asset Management first reported a position in HZNP in Q4 2016 and held it in 15 quarters. The position peaked at $4.62M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Wolverine Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Wolverine Asset Management sold 39,899 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $4.62M.
Wolverine Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016 and held it in 15 quarters.
Wolverine Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $4.62M in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Wolverine Asset Management's 13F filing for Q4 2023, filed 1 Feb 2024.